Di Iorio A - Search Results

1

Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease.

Onofrj M, Di Iorio A, Carrarini C, Russo M, Franciotti R, Espay AJ, Boylan LS, Taylor JP, Di Giannantonio M, Martinotti G, Valente EM, Thomas A, Bonanni L, Delli Pizzi S, Dono F, Sensi S. Onofrj M, et al. Among authors: di giannantonio m, di iorio a. Mov Disord. 2021 Dec;36(12):2840-2852. doi: 10.1002/mds.28745. Epub 2021 Aug 24. Mov Disord. 2021. PMID: 34427338 Free PMC article.

2

Muscle quality, physical performance, and comorbidity are predicted by circulating procollagen type III N-terminal peptide (P3NP): the InCHIANTI follow-up study.

Pellegrino R, Paganelli R, Di Iorio A, Bandinelli S, Moretti A, Iolascon G, Sparvieri E, Tarantino D, Ferrucci L. Pellegrino R, et al. Among authors: di iorio a. Geroscience. 2024 Feb;46(1):1259-1269. doi: 10.1007/s11357-023-00894-3. Epub 2023 Aug 2. Geroscience. 2024. PMID: 37532926 Free PMC article.

3

Headache in children with centrotemporal spikes.

Melchionda D, Verrotti A, Chiarelli F, Domizio S, Sabatino G, Mucedola T, D'Andreamatteo G, Toma L, Di Iorio A, Onofrj M. Melchionda D, et al. Among authors: di iorio a. Neurophysiol Clin. 1999 Feb;29(1):90-100. doi: 10.1016/S0987-7053(99)80043-4. Neurophysiol Clin. 1999. PMID: 10093820 Clinical Trial.

4

Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.

Onofrj M, Thomas A, Iacono D, Di Iorio A, Bonanni L. Onofrj M, et al. Among authors: di iorio a. Eur Neurol. 2001;46(1):11-6. doi: 10.1159/000050749. Eur Neurol. 2001. PMID: 11455177

5

Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.

Onofrj M, Thomas A, Luciano AL, Iacono D, Di Rollo A, D'Andreamatteo G, Di Iorio A. Onofrj M, et al. Among authors: di rollo a, di iorio a. Clin Neuropharmacol. 2002 Jul-Aug;25(4):207-15. doi: 10.1097/00002826-200207000-00004. Clin Neuropharmacol. 2002. PMID: 12151908 Clinical Trial.

6

Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up.

Onofrj M, Thomas A, D'Andreamatteo G, Iacono D, Luciano AL, Di Rollo A, Di Mascio R, Ballone E, Di Iorio A. Onofrj M, et al. Among authors: di rollo a, di mascio r, di iorio a. Neurol Sci. 2002 Sep;23 Suppl 2:S91-4. doi: 10.1007/s100720200085. Neurol Sci. 2002. PMID: 12548359

7

The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia.

Onofrj M, Thomas A, Iacono D, Luciano AL, Di Iorio A. Onofrj M, et al. Among authors: di iorio a. Clin Neuropharmacol. 2003 Sep-Oct;26(5):239-51. doi: 10.1097/00002826-200309000-00008. Clin Neuropharmacol. 2003. PMID: 14520164 Clinical Trial.

8

Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.

Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Thomas A, et al. Among authors: di iorio a. J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):141-3. J Neurol Neurosurg Psychiatry. 2004. PMID: 14707325 Free PMC article. Clinical Trial.

9

End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease.

Thomas A, Bonanni L, Di Iorio A, Varanese S, Anzellotti F, D'Andreagiovanni A, Stocchi F, Onofrj M. Thomas A, et al. Among authors: di iorio a. J Neurol. 2006 Dec;253(12):1633-9. doi: 10.1007/s00415-006-0320-z. J Neurol. 2006. PMID: 17219034 Clinical Trial.

10

Pathological gambling in Parkinson disease is reduced by amantadine.

Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Thomas A, et al. Among authors: di iorio a. Ann Neurol. 2010 Sep;68(3):400-4. doi: 10.1002/ana.22029. Ann Neurol. 2010. PMID: 20687121 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

173 results

Search Page